Researchers propose 12 candidate markers to speed longevity-drug screening

Researchers proposed 12 candidate biological indicators on September 17 that could help scientists identify promising longevity interventions sooner. Published in Frontiers in Science, the framework addresses a central obstacle in aging research: determining whether a treatment deserves further testing without first waiting for animals to complete their lifespans.

The article synthesizes existing mouse research and presents a research roadmap. It reports neither a new human trial nor a validated clinical test. Its immediate relevance is to experimental screening, with applications to human prevention research remaining a longer-term possibility.

What the proposed indicators measure

The authors call the measurements aging rate indicators, or ARIs. Their proposal is to identify biological patterns shared by mice whose lifespans have been extended through different interventions, including drugs, dietary changes and genetic alterations.

Candidates include activity in the mTORC1 signaling pathway, the balance of inflammatory and anti-inflammatory immune cells in fat, and proteins involved in communication among tissues. The working question is whether these measurements can distinguish animals exposed to effective interventions from comparable controls.

In its accompanying announcement, Frontiers explains that an ARI would ideally reveal a change in aging-related physiology from a measurement taken at one age. That could help researchers select compounds for more demanding studies. The publisher emphasizes that the candidates are not ready for clinical use and require testing across species and in humans.

Why faster screening matters

An important foundation is the National Institute on Aging’s Interventions Testing Program. According to NIA, the program tests compounds in genetically heterogeneous male and female mice at three institutions: the Jackson Laboratory, the University of Michigan and the University of Texas Health Science Center at San Antonio.

Shared procedures and simultaneous testing help assess whether findings reproduce across locations. Initial pilot work examines matters such as toxicity, drug exposure and stability in food before compounds proceed into lifespan testing. Promising agents can receive further evaluation at different treatment timings or with additional measures of health and pathology.

The principal survival experiments follow animals until natural death or severe illness meeting the study’s endpoint criteria. NIA says both positive and negative lifespan findings are submitted for publication. This design provides an outcome against which a proposed shortcut can be judged: whether an early molecular signal actually anticipates longer survival or better later-life function.

Frontiers’ announcement describes full mouse lifespan studies as taking three to four years. A reliable preliminary screen could therefore make choosing the next experiment substantially more efficient, although that efficiency remains conditional on validation.

A marker response can mislead

An accompanying viewpoint by University of Pennsylvania researchers Joseph McGaunn and Joseph Baur identifies several reasons for caution. A proposed indicator can change for reasons unrelated to longevity, and different organs may not age at the same pace.

The viewpoint also questions whether candidate indicators can capture differences between male and female responses to interventions. A favorable molecular signal could coexist with a separate harmful effect, complicating interpretation.

Short experiments create another problem: they may miss harms that emerge slowly. The commentators argue that marker-based screening should complement conventional studies of lifespan and healthspan, with eventual clinical benefit measured directly in the relevant population.

The lead article acknowledges that much of the candidate-marker research comes from one laboratory group and needs independent replication. For healthspan research, the practical advance is a testable strategy for prioritizing experiments. Whether these indicators can reliably identify interventions that preserve human function or prevent disease remains unanswered.